A phase 2 pivotal, efficacy study of AVA6000 as a first line treatment in patients with soft tissue sarcoma
Latest Information Update: 03 Oct 2023
At a glance
- Drugs AVA 6000 (Primary)
- Indications Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- 28 Sep 2023 According to an Avacta media release, this is potentially pivotal trial subject to receiving the necessary regulatory approvals. This trial is planned to start during 2024
- 22 Sep 2023 New trial record
- 20 Sep 2023 According to an Avacta media release, this study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA).